HomeFilePharmacology

Pharmacology

LpA: 30-Year Cardiovascular Followup in Primary Prevention Cohorts

For years, treating dyslipidemia mainly focused on reducing LDL cholesterol (LDL-C) with statins, which had shown benefits...

ACC 2024 | REDUCE AMI: Beta-Blockers after Myocardial Infarction and Preserved Ejection Fraction

Most clinical trials have shown benefits of beta blockers after acute myocardial infraction, including patients with extensive...

ACC 2024 | ULTIMATE-DAPT Trial

The international guidelines recommend the use of dual antiplatelet therapy (DAPT) with aspirin plus a P2Y12 inhibitor...

Clopidogrel Monotherapy Beyond 12 months: Long Term Analysis of the STOPDAPT-2

Short dual antiplatelet therapy (DAPT) has shown benefits in patients receiving drug eluting stents (DES), reducing bleeding...

Transcatheter Mitral Valve Replacement: DOAC or VKA?

Severe mitral disease is common and currently constitutes a frequent cause of hospitalization and death. While surgery...

Use of Apixaban and Post TAVR Valve Thrombosis

TAVR can be associated to early valve thrombosis, characterized by thrombi formation near or attached to the...

Cilostazol in Diabetic Patients with Endovascular Peripheral Revascularization: One Step Beyond Symptom Improvement

In patients with peripheral vascular disease (PVD), the presence of diabetes has been significantly associated with increased...

Optimal Duration of DAPT with Oral Anticoagulation After PCI?: 1 Month vs. 3 Months

While the benefits of dual antiplatelet therapy (DAPT) with aspirin and a P2Y12 inhibitor are recognized, its...